John Sy1, Charles E McCulloch2, Kirsten L Johansen1,3. 1. Division of Nephrology, Tibor Rubin Veterans Affairs Medical Center, Long Beach, California, USA. 2. Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA. 3. Division of Nephrology, San Francisco Veterans Affairs Medical Center, San Francisco, California, USA.
Abstract
INTRODUCTION: Frailty and depression are highly prevalent in the dialysis population, but the association between them, the risk factors for their development, and their independent associations with mortality have not been studied. METHODS: We examined 771 patients enrolled in the ACTIVE/ADIPOSE prevalent dialysis cohort study. Fried's frailty phenotype and the Center for Epidemiologic Studies Depression score were used to determine frailty and presence of depressive symptoms, respectively. We assessed the baseline association between frailty and depressive symptoms, whether one entity is a risk factor for development of the other, and associations between frailty and depressive symptoms with mortality. FINDINGS: At baseline, 13.1% of our population screened positive for depressive symptoms, 21.8% met criteria for frailty, and 10.0% met criteria for both. During follow-up, 26.6% of our population developed frailty and 12.7% developed depressive symptoms. Using multivariable logistic regression, baseline depressive symptoms were associated with 2.14-fold higher odds of being frail at baseline (95% confidence interval [CI] 1.45-3.17) and with a 2.16-fold higher odds of incident frailty during follow-up (95% CI 1.22-3.82). However, baseline frailty was not associated with incident depressive symptoms. Frailty and depressive symptoms were independent predictors of mortality in time-varying survival analysis (meeting frailty criteria: hazard ratio [HR] 1.53, 95% CI 1.05-2.23; depressive symptoms: HR 2.21, 95% CI 1.50-3.25). DISCUSSION: Frailty and depressive symptoms remained highly prevalent over time and were strongly associated with one another and independently associated with mortality among dialysis patients. Future studies should investigate whether interventions for depression could potentially mitigate the appearance of frailty and its associated poor outcomes.
INTRODUCTION: Frailty and depression are highly prevalent in the dialysis population, but the association between them, the risk factors for their development, and their independent associations with mortality have not been studied. METHODS: We examined 771 patients enrolled in the ACTIVE/ADIPOSE prevalent dialysis cohort study. Fried's frailty phenotype and the Center for Epidemiologic Studies Depression score were used to determine frailty and presence of depressive symptoms, respectively. We assessed the baseline association between frailty and depressive symptoms, whether one entity is a risk factor for development of the other, and associations between frailty and depressive symptoms with mortality. FINDINGS: At baseline, 13.1% of our population screened positive for depressive symptoms, 21.8% met criteria for frailty, and 10.0% met criteria for both. During follow-up, 26.6% of our population developed frailty and 12.7% developed depressive symptoms. Using multivariable logistic regression, baseline depressive symptoms were associated with 2.14-fold higher odds of being frail at baseline (95% confidence interval [CI] 1.45-3.17) and with a 2.16-fold higher odds of incident frailty during follow-up (95% CI 1.22-3.82). However, baseline frailty was not associated with incident depressive symptoms. Frailty and depressive symptoms were independent predictors of mortality in time-varying survival analysis (meeting frailty criteria: hazard ratio [HR] 1.53, 95% CI 1.05-2.23; depressive symptoms: HR 2.21, 95% CI 1.50-3.25). DISCUSSION: Frailty and depressive symptoms remained highly prevalent over time and were strongly associated with one another and independently associated with mortality among dialysis patients. Future studies should investigate whether interventions for depression could potentially mitigate the appearance of frailty and its associated poor outcomes.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Antonio Alberto Lopes; Justin M Albert; Eric W Young; Sudtida Satayathum; Ronald L Pisoni; Vittorio E Andreucci; Donna L Mapes; Nancy A Mason; Shunichi Fukuhara; Björn Wikström; Akira Saito; Friedrich K Port Journal: Kidney Int Date: 2004-11 Impact factor: 10.612
Authors: Michael G Shlipak; Linda F Fried; Casey Crump; Anthony J Bleyer; Teri A Manolio; Russell P Tracy; Curt D Furberg; Bruce M Psaty Journal: Circulation Date: 2003-01-07 Impact factor: 29.690
Authors: Antonio Alberto Lopes; Jennifer Bragg; Eric Young; David Goodkin; Donna Mapes; Christian Combe; Luis Piera; Philip Held; Brenda Gillespie; Friedrich K Port Journal: Kidney Int Date: 2002-07 Impact factor: 10.612
Authors: Nadia M Chu; Xiaomeng Chen; Silas P Norman; Jessica Fitzpatrick; Stephen M Sozio; Bernard G Jaar; Alena Frey; Michelle M Estrella; Qian-Li Xue; Rulan S Parekh; Dorry L Segev; Mara A McAdams-DeMarco Journal: Am J Nephrol Date: 2020-07-08 Impact factor: 3.754
Authors: Mara A McAdams-DeMarco; Sarah E Van Pilsum Rasmussen; Nadia M Chu; Dayawa Agoons; Ronald F Parsons; Tarek Alhamad; Kirsten L Johansen; Stefan G Tullius; Raymond Lynch; Meera N Harhay; Maya K Rao; Joseph Berger; Matthew Cooper; Jane C Tan; XingXing S Cheng; Kenneth J Woodside; Sandesh Parajuli; Krista L Lentine; Bruce Kaplan; Dorry L Segev; Jon A Kobashigawa; Darshana Dadhania Journal: Transplantation Date: 2020-02 Impact factor: 5.385
Authors: Benjamin M Anderson; Muhammad Qasim; Gonzalo Correa; Felicity Evison; Suzy Gallier; Charles J Ferro; Thomas A Jackson; Adnan Sharif Journal: Clin Kidney J Date: 2021-07-16
Authors: Gabriel A J Vasquez-Goñi; Basilio M Papuico-Romero; Diego Urrunaga-Pastor; Fernando M Runzer-Colmenares; José F Parodi Journal: Heliyon Date: 2021-12-20